Key facts
- This page summarizes Pascal E. R. Girin's Form 4 filing for ClearPoint Neuro, Inc. (CLPT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 May 2022, 16:30.
Pascal E. R. Girin - 25 May 2022 Form 4 Insider Report for ClearPoint Neuro, Inc. (CLPT)
- Reporting relationship
- Director
- Issuer ticker
- CLPT
- Reported as of
- 25 May 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 May 2022, 16:30:39 UTC
- Prior SEC filing
- 05 Apr 2022
- Next SEC filing
- 06 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- Richard F. Mattern, by Power of Attorney for Pascal E.R. Girin
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pascal E. R. Girin filed Form 4 for ClearPoint Neuro, Inc. (CLPT) on 27 May 2022.
Change
- Previous filing in this sequence was filed on 05 Apr 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLPT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +9,269
- Change %
- +24%
- Price
- $0.000000
- Shares after
- 47,379
- Date
- 25 May 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLPT
transaction
Derivative
Stock Options (right to buy)
Award
- Transaction value
- $0
- Shares
- +6,179
- Change %
- Price
- $0.000000
- Shares after
- 6,179
- Date
- 25 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,179
- Exercise price
- $9.71
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares are restricted stock and will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2023 annual meeting of stockholders.
Footnote F2
The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2023 annual meeting of stockholders.